Follow
Olivier Dormond
Olivier Dormond
Department of Visceral Surgery
Verified email at chuv.ch
Title
Cited by
Cited by
Year
Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation
A Sabine, Y Agalarov, H Maby-El Hajjami, M Jaquet, R Hägerling, ...
Developmental cell 22 (2), 430-445, 2012
4082012
NSAIDs inhibit αVβ3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis
O Dormond, A Foletti, C Paroz, C Rüegg
Nature medicine 7 (9), 1041-1047, 2001
3842001
PI3K and AKT: unfaithful partners in cancer
S Faes, O Dormond
International journal of molecular sciences 16 (9), 21138-21152, 2015
2962015
Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12
AK Singh, RK Arya, AK Trivedi, S Sanyal, R Baral, O Dormond, ...
Cytokine & growth factor reviews 24 (1), 41-49, 2013
2222013
Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis
C Rüegg, O Dormond, A Mariotti
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1654 (1), 51-67, 2004
2052004
Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase …
M Bezzi, M Hasmim, G Bieler, O Dormond, C Rüegg
Journal of Biological Chemistry 278 (44), 43603-43614, 2003
2012003
Prostaglandin E2 promotes integrin αVβ3-dependent endothelial cell adhesion, Rac-activation, and spreading through cAMP/PKA-dependent signaling
O Dormond, M Bezzi, A Mariotti, C Ruegg
Journal of Biological Chemistry 277 (48), 45838-45846, 2002
1962002
Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?
C Rüegg, O Dormond, A Foletti
Endothelium 9 (3), 151-160, 2002
1942002
DLL4 promotes continuous adult intestinal lacteal regeneration and dietary fat transport
J Bernier-Latmani, C Cisarovsky, CS Demir, M Bruand, M Jaquet, ...
The Journal of clinical investigation 125 (12), 4572-4586, 2015
1712015
The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells
O Dormond, JC Madsen, DM Briscoe
Journal of Biological Chemistry 282 (32), 23679-23686, 2007
1562007
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells
B Mastelic-Gavillet, B Navarro Rodrigo, L Décombaz, H Wang, ...
Journal for immunotherapy of cancer 7, 1-16, 2019
1502019
Tumor heterogeneity and cancer stem cell paradigm: updates in concept, controversies and clinical relevance
AK Singh, RK Arya, S Maheshwari, A Singh, S Meena, P Pandey, ...
International journal of cancer 136 (9), 1991-2000, 2015
1412015
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
A Weiss, X Ding, JR Van Beijnum, I Wong, TJ Wong, RH Berndsen, ...
Angiogenesis 18, 233-244, 2015
1362015
Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma
M Zoetemelk, M Rausch, DJ Colin, O Dormond, P Nowak-Sliwinska
Scientific reports 9 (1), 7103, 2019
1262019
Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease
N Brakch, O Dormond, S Bekri, D Golshayan, M Correvon, L Mazzolai, ...
European heart journal 31 (1), 67-76, 2010
1132010
Modulation of mTOR signalling triggers the formation of stem cell-like memory T cells
G Scholz, C Jandus, L Zhang, C Grandclément, IC Lopez-Mejia, ...
EBioMedicine 4, 50-61, 2016
1122016
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
D Roulin, Y Cerantola, A Dormond-Meuwly, N Demartines, O Dormond
Molecular cancer 9, 1-4, 2010
1052010
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
D Roulin, Y Cerantola, A Dormond-Meuwly, N Demartines, O Dormond
Molecular cancer 9, 1-4, 2010
1052010
Resistance to mTORC1 inhibitors in cancer therapy: from kinase mutations to intratumoral heterogeneity of kinase activity
S Faes, N Demartines, O Dormond
Oxidative medicine and cellular longevity 2017, 2017
842017
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
D Roulin, L Waselle, A Dormond-Meuwly, M Dufour, N Demartines, ...
Molecular cancer 10, 1-12, 2011
812011
The system can't perform the operation now. Try again later.
Articles 1–20